Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
568
resultados
Última actualización
17/10/2026 [07:24:00]
Resultados 550 a 568 de 568
Resumen de: US20260272346A1
0000 A method for measuring oxygen saturation includes determining a difference in voltage value for a light emitting diode based on a first voltage at the light emitting diode for a first current and a second voltage at the light emitting diode for a second current and determining a temperature for the light emitting diode based on the difference in voltage value. The method further includes determining an intensity of a received photonic signal corresponding to an output photonic signal output using the light emitting diode and determining an oxygen saturation level based on the intensity of the received photonic signal and the temperature for the light emitting diode. The method further includes outputting an indication of the oxygen saturation level.
Resumen de: US20260273187A1
Drug delivery system, injection device, transfer apparatus, vial holder and method of administering and transferring are disclosed which provide for passive warming of chilled injectable transferred through the transfer apparatus and into the injection device. The injection device may include a skin-facing surface including a skin boundary displacement extension or structure around a needle injection site to create a high pressure zone in the tissue. Radio frequency tracking and monitoring features for tracking patient compliance also may be provided.
Resumen de: US20260272364A1
The present disclosure describes a method for neuromodulating a subject, comprising providing (i) a cognitively engaging content, and (ii) a gamma oscillation inducing waveform, wherein said gamma oscillation inducing waveform: comprises an intensity that renders said gamma oscillation inducing waveform imperceptible to said subject; and causes a therapeutic improvement in a cognitive function, thereby neuromodulating said subject.
Resumen de: US20260273176A1
A method of providing a personal drug injection system is disclosed. The method comprises determining at least one anthropometric characteristic from a person, and providing a plurality of types of personal drug injection systems. Each personal drug injection system of a personal drug injection system type is configured so as to fit with a part of the person's body that is intended to receive an injectable drug, and includes a drug injection location set that includes at least one defined drug injection location corresponding to a location of a drug injection site on the part of the person's body when the personal drug injection system is disposed on the part of the person's body. Each personal drug injection system type is associated with a defined range of anthropometric characteristics that is different to the defined range of anthropometric characteristics associated with the other personal drug injection system types, and each personal drug injection system type has an associated drug injection location set that is different to the drug injection location set of the other personal drug injection system types. The method also involves using the determined anthropometric characteristic and the defined ranges of anthropometric characteristics to select one of the personal drug injection system types from the plurality of personal drug injection system types already manufactured, and providing the person with the selected personal drug injection system type.
Resumen de: US20260272454A1
An apparatus includes a first stapling assembly, a plurality of staples a plurality of staple drivers, and a second stapling assembly portion. The first stapling assembly portion has a deck surface defining a plurality of apertures. The staple drivers can drive the plurality of staples through the staple apertures of the deck surface. The second stapling assembly can couple with the first stapling assembly portion. The second stapling assembly portion has a section that overlies the deck surface. At least one of the first or second stapling assembly portions include a first support feature that inhibits deflection of the deck surface during stapling.
Resumen de: EP4249257A1
A curable composition containing a radical-polymerizable monomer and a hard solid component having a volume average particle diameter of 10 nm or greater and 1,000 nm or less is provided. The content of the hard solid component is 3% by volume or greater and 40% by volume or less. The difference (n1-n2) between the refractive index (n1) of a cured product of any other component than the hard solid component and the refractive index (n2) of the hard solid component is 0.04 or greater.
Resumen de: US20260272637A1
A bio-compatible implant that is adapted for use in repairing soft tissue damage includes a fibrous scaffold having a length, a width and a thickness. The fibrous scaffold includes a plurality of fibers oriented in three orthogonal directions. In some instances, the three orthogonal directions align with the length, width and thickness of the fibrous scaffold. In some cases, two of the three orthogonal directions may be offset with respect to the length and width of the fibrous scaffold.
Resumen de: US20260278782A1
An information processing device includes, at least one memory storing instructions, and at least one processor configured to execute the instructions to, acquire one or a plurality of endoscopic images, detect a polyp candidate from the endoscopic image, calculate a first type score indicating a polyp likelihood regarding the polyp candidate, store an image of the polyp candidate and the first type score in a storage unit, determine whether the polyp candidate is identical to one or a plurality of other polyp candidates stored in the storage unit; and calculate a first type integrated score by integrating the first type score and a first type score related to one or a plurality of the other polyp candidates stored in the storage unit when the candidates are determined identical to each other.
Resumen de: US20260273132A1
This invention relates to an implant (10), including a support arrangement (12) manufactured from a form of a porous material, for receiving and supporting stem cells (14) in a supported condition, for receiving a medium in the form of a neural basal and neural induction medium mixture (20) and the support arrangement (12) being shaped and sized to conform to and be received complementally by an implant zone (16). The implant zone (16) being a space defined by an excised portion of a subject's spinal cord (18). The neural basal and neural induction medium mixture (20) provides nutrients for the development of the stem cells (14) and the growth factors, in form of neurotrophin 3, neurotrophin 4 and brain-derived neurotrophic factor (BDNF) encourage and control development of the stem cells (14), the growth factors typically being constituents of the medium mixture (20).
Resumen de: US20260279508A1
The present invention provides a new integrated platform that allows the validation of production processes, the standardization and the evaluation of complex natural products, allowing the characterization of the complex mixture contained within products with a therapeutic and/or healthy effect based on or consisting of from natural substances “as an entire system”, without limiting their characterization to a reductionistic chemical approach aimed at a single marker, but rather integrating qualitative-quantitative data and fingerprint characterization metabolomics of the mixture with physical and biophysical activity data thus providing a characterization of the product which is the basis of the validation process of the production process which allows to guarantee reproducibility between different batches of this product in terms of efficacy and safety. The analytical platform described here allows us to guarantee the complex natural product as a whole, taking into consideration all its quality and efficacy properties in order to guarantee the reproducibility of the effect and safety through a multidimensional analytical approach.
Resumen de: US20260275290A1
0000 The invention provides a method for producing a three dimensional thymic like structure, the method comprising: a) providing pluripotent cells from a recipient with a nucleic acid molecule comprising a FOXN1 sequence, and b) inducing said pluripotent cell to differentiate into thymic epithelium in a scaffold suitable for transplantation, as well as related methods, compositions or uses.
Resumen de: US20260274931A1
0000 Disclosed herein are methods of conducting clinical trials in Alzheimer's disease (AD). Methods of selecting a medicament and treating an AD subject are disclosed. Methods, systems, kits, and devices for selecting a subject in AD clinical trials and treatment protocols are disclosed herein.
Resumen de: US20260272788A1
The present invention relates to a mixture, for 3D printing, particularly a resin for 3D printing comprising—a monomer, oligomer or polymer, or a mixture thereof, comprising at least one acrylate or methacrylate subunit, and—a lactam, characterized in that the lactam concentration is 0.001 to 0.3 wt %, particularly the lactam concentration is 0.001 to 0.15 wt %, more particularly the lactam concentration is 0.01 to 0.1 wt %. Furthermore, the present invention relates to a polymer, in particular a dental polymer or an otoplastic polymer comprising polymerised monomers and/or oligomers or polymers and a lactam, as well as a medical product comprising said polymer.
Resumen de: US20260273859A1
Apparatus for producing three-dimensional screen-printed workpieces, in particular a 3D screen-printing machine, having a printing device for the layerwise production of at least one screen-printed workpiece in a plurality of printing operations and having a transport device for the automated transport of at least one screen-printed workpiece and/or of a workpiece carrier towards and/or away from the printing device, wherein the transport device has a carrying section for the at least form-fitting reception of a workpiece carrier.
Resumen de: US20260272305A1
0000 A system for analyzing a reflected signal during a laser procedure can include a surgical scope. A first light source emitter can be configurable to emit a first signal having a first (e.g., a non-visible) spectrum. A second light source emitter can be configurable to emit a second signal having a second spectrum (e.g., a visible or infrared (IR) spectrum). Each of the first or the second light source emitters can be coupled to or included within the surgical scope. The system can include an optical sensor configurable to detect and analyze a third signal returned from the surface of an object in response to the emitted second signal. The returned third signal can be analyzed to determine whether a reflected absolute or relative intensity or an absolute or relative spectral signature meets at least one criterion, thereby triggering at least one of: warning a user or adjusting the first signal.
Resumen de: US20260277188A1
The invention relates to a system (1) for forming a deep-drawn object, wherein the system (1) comprises: —a generative manufacturing device (2) configured to generate a three-dimensional (3D) object on a build platform (3) and—a deep-drawing device (4), characterized in that the deep-drawing device (4) comprises a receiving structure (41) configured to receive the build platform (3), particularly the build platform (3) with the 3D object (5) on the build platform (3), such that when the build platform (3) is received by the receiving structure (41), the deep-drawn object can be generated by the deep-drawing device (4) based on the 3D object (5). The invention also relates to a deep-drawing device (4) and a method for forming a deep-drawn object.
Resumen de: US20260273136A1
Provided herein are hydrogels nanoengineered as a 3D-printed wearable electronic skin conformable to human skin and methods for nanoengineering the hydrogels. The hydrogel may be nanoengineered to have a crosslinked pullulan-SH/polydopamine/molybdenum disulfide network (Pul-SH/PDA/MoS2). Also provided are methods for detecting and monitoring physiological changes via the wearable electronic skin and for diagnosing a disease or disorder based on the physiological changes.
Nº publicación: US20260279595A1 17/09/2026
Solicitante:
UTI LP [CA]
UTI Limited Partnership
Resumen de: US20260279595A1
Provided are computer-implemented systems and methods for generating a health outcome prediction, including: receiving user data, the user data comprising passively collected data by a passive data collection monitoring device associated with the user; self-reported health metrics associated with the user; receiving clinical health outcome data, the clinical health outcome data comprising at least one health outcome based on clinical data; extracting a plurality of variables from the user data; providing the plurality of variables and the clinical health outcome data as inputs to at least one machine learning model to identify at least one selected variable from the plurality of variables, having an associated predictive value to the clinical health outcome data; generating based on the at least one selected variable, an individualized prediction algorithm for generating the health outcome prediction; applying the individualized prediction algorithm to the user data to generate the health outcome prediction.
BOPI
Sede Electrónica
